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Abstract High serum albumin levels during ischemic stroke
(IS) decrease the risk of a poor outcome. This study aimed to
determine whether serum albumin levels within the first days
after IS correlate with radiological and biochemical markers of
brain tissue damage. Fifty-six IS patients were enrolled into
the study. Neurological examinations were based on the Na-
tional Institute of Health Stroke Scale. Serum albumin levels
and S100BB were evaluated using commercially available
ELISA kits. The albumin decrease index (ADI) was calculated
as the difference between serum albumin levels measured on
days 1 and 10 of IS. All parameters were estimated on the 1st,
3rd, 5th, and 10th days of IS, and the volume of ischemic
focus was measured on the 10th day. Mean serum albumin
levels were decreased during acute IS. There were correlations
between the ADI and mean S100BB serum levels (r = 0.36,
p < 0.05), the volume of ischemic focus (r = 0.39, p < 0.05),
and the patients’ neurological state when measured on day 10
of IS (r = 0.59, p < 0.001). A decrease in serum albumin levels
during the acute phase of IS corresponds to a worse neurolog-
ical state as a result of a large ischemic focus with intense
catabolic processes.
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Abbreviations
ADI Albumin decrease index (difference in serum
albumin levels measured on days 1 and 10 after
ischemic stroke)
BBB Blood-brain barrier
IF Ischemic focus volume
IS Ischemic stroke
NIHSS National Institute of Health Stroke Scale
Introduction
Previous studies have highlighted the favorable relationship of
serum albumin levels on the outcome of patients experiencing
ischemic stroke (IS) (Babu et al. 2013; Baltanas et al. 2009;
Belayev et al. 2002). Small ischemic lesions are independently
correlated with high serum albumin levels (Boselli et al.
2012). Moreover, a low serum albumin level is one of the
predictive factors for a first-ever non-embolic stroke in older
individuals (Buttner et al. 1997). Some experimental studies
have suggested a neuroprotective effect of albumin either by
reducing brain edema (Chen et al. 2013) or by its antioxidative
or antiapoptotic properties (Ciuffetti et al. 1988). Adequate
levels of serum albumin lead to an improvement in microcir-
culatory flow, viscosity of plasma, and oxygen transport ca-
pacity (Defazio et al. 2012). Serum albumin levels also have a
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beneficial influence on the immune system (Dziedzic et al.
2012). Local, low-dose, cold albumin infusion into the ische-
mic area enhances neuroprotection (Dziedzic et al. 2006). Al-
bumin treatment exerts a significant therapeutic effect after
ischemia by augmenting collateral perfusion (Dziedzic et al.
2004).
This study aimed to determine whether baseline serum al-
bumin levels or a change in levels within the first few days
after IS correlates with the patient’s neurological state and
with radiological or biochemical markers of brain tissue
damage.
Subjects and Methods
Fifty-six patients, who had acute IS confirmed in a computed
tomography (CT) scan and were admitted to the Stroke Unit at
the Department of Neurology, Medical University of Lublin,
were prospectively enrolled into the study. The main qualifi-
cation criterion was the time when the patient was seen with-
out focal neurological symptoms that did not exceed 12 h.
Other neurological disorders that could influence the
S100BB serum level excluded patients from the study.Written
informed consent was obtained from each patient (or from
family members when necessary). The local ethics committee
accepted the protocol of the study.
The characteristics of the study and control groups are
shown in Table 1. Neurological examinations were performed
on days 1, 3, 5, and 10 from admission to the hospital based on
the National Institute of Health Stroke Scale (NIHSS).
CT scans were performed without contrast scanning, using
64-row multidetector CT (LightSpeed VCT with Advantage
Window 4.3 workstation). The first CT scan was performed
upon admission to hospital and a second scan was performed
on 10 days after the stroke for estimation of ischemic focus
volume (IF). CT scans were 2.5 mm in the posterior fossa and
5 mm in other areas of the brain. IF was measured with the
planimetric method, using an additional workstation for mea-
suring IF in the three-dimensional option.
Five milliliters of venous blood samples were obtained on
1, 3, 5 and 10 days of IS for the measurement of albumin and
S100BB protein levels. Patients were fasted for at least 8 h
before blood collection. After the clot forming the blood was
centrifuged and serum was transferred into the temperature
−70 for further analysis.
Serum albumin levels were evaluated with usage of
commercially available enzyme-linked immunosorbent as-
say (ELISA) kit (Cell Biolabs, Inc., San Diego, CA) ac-
cording to the manufacturer’s instructions. Before the anal-
ysis, the sera were diluted 1:106 with phosphate-buffered
saline (PBS) to adjust the albumin concentration to the
range of sensitivity of the applied method. The albumin
decrease index (ADI) was calculated as the difference in
baseline serum albumin levels measured on days 1 and 10
of stroke.
S100BB serum levels were measured as the biochemical
marker of traumatic and vascular brain damage (Laribi et al.
2014; Brea et al. 2009; Ishibashi and Funakoshi 2008) and as
an indicator of blood-brain barrier (BBB) integrity (Koh and
Lee 2014). Commercially available ELISA kit (CanAg Diag-
nostics AB, Gothenburg, Sweden) was applied to S100BB
analysis according to the manufacturer’s instructions. The de-
tection limit of the S100BB protein was 10 pg/ml. All values
Table 1 Patients’ characteristics
Mean age (range) 72.8 (48–93) years
Sex Male n = 24, female n = 32
OCSP classification TACI n = 6
PACI n = 31
LACI n = 10
POCI n = 9
Thrombolytic therapy n = 3
OCSP The Oxfordshire Community Stroke Project classification, TACI
total anterior circulation infarct, PACI partial anterior circulation infarct,
LACI lacunar infarct, POCI posterior circulation infarct
Table 2 Changes in albumin levels, S100BB serum levels, and NIHSS scores during the acute phase of ischemic stroke
Day 1 Day 3 Day 5 Day 10 p
Albumin (g/dl) 4.04 (0.42) 3.80 (0.44) 3.80 (0.43) 3.72 (0.49) 0.006*
S100BB (pg/ml) 51.02 [30.15; 77.17] 57.95 [27.49; 109.06] 52.96 [30.80; 92.56] 36.00 [25.56; 59.24] 0.060†
NIHSS 13 [7; 18] 10.5 [5; 16] 9 [4.25; 15] 9 [3.25; 14] 0.045†
Volume of IF (ml) 17.00 [2.09; 67.48]
ADI 0.32 [−0.10; 0.60]
The volume of ischemic focus (IF) and the albumin decrease index (ADI) were estimated on day 10 of stroke. Values are expressed as mean (SD) or
median (1st quartile; 3rd quartile)
*ANOVA
†Kruskal-Wallis test
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below the detection limit were rendered as zero and were not
applied in calculations.
Spearman’s rank correlation was applied to calculate the
relationship between biochemical parameters and CT find-
ings or NIHSS values. Significant values were considered
when p was <0.05. Statistical analysis was performed with
the use of the computer-assisted software, GraphPad InStat
v. 3.06. (San Diego, USA).
Results
Baseline serum albumin levels were not correlated with mean
S100BB serum levels (r = 0.16, p > 0.05) or the patients’
neurological state (correlation with NIHSS on day 10 of
stroke: r = 0.12, p > 0.05). However, baseline serum albumin
levels predicted IF (r = 0.35, p < 0.05). ADI was significantly
correlated with mean S100BB serum levels (r = 0.36,
p < 0.05), IF (r = 0.39, p < 0.05), and the patients’ neurological
state (NIHSS score) on day 10 of stroke (r = 0.59, p < 0.001).
The ADI was not significantly different between different
subgroups of the Oxfordshire Community Stroke Project
(OCSP) classification (p > 0.05, Kruskal-Wallis test). The
values of serum albumin and S100BB protein levels are
shown in Table 2.
Discussion
This study showed a gradual decrease in serum albumin levels
in patients during acute IS. We observed interesting relation-
ships between ADI and IF mean S100BB levels, and the
NIHSS score. A greater IF and higher S100BB serum levels,
which partially reflect the size of ischemic focus as well as the
state of the BBB, were observed in patients with a greater
ADI. Some experimental and histological studies have shown
extravasation of plasma proteins into the ischemic focus in
angiogenesis during clinical recovery (Kapural et al. 2002).
In addition, ADI can reflect an increase in the metabolic rate
within the infarcted area or a decrease in albumin synthesis
during the acute phase of IS. Release of hormones, such as
glucagon, catecholamines, and corticosteroids, results in in-
tensification of numerous catabolic pathways, including pro-
teolysis. These processes are connected with the degradation
of serum albumin, which then leads to hypoalbuminemia.
Low serum albumin levels in patients with IS are associated
with higher serum cortisol levels (Kisialiou et al. 2012). We
suggest that ADI during stroke can indirectly reflect the inten-
sity of the response within the ischemic focus. A prolonged
and intense catabolic state might also lead to insufficiency of
immune responses that make patients prone to numerous com-
plications, such as infections (Liu 1988) or loss of weight
(Milionis et al. 2005). This may play a part in a worse
outcome after stroke, which was confirmed in our study.
Oral supplementation of essential amino acids may reduce
the occurrence of nosocomial infection in patients with
brain injury (Wang et al. 2013).
We conclude that worsening of the neurological state cor-
responds to a decrease in serum albumin levels as a result of a
large ischemic focus with intense catabolic processes during
acute IS.
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